Scientific Leadership

In 2006, Veda N. Giri, MD, was appointed Director of Prostate Cancer Risk Assessment.

The program offers education, risk assessment and screening to men who are at an increased risk of prostate cancer because of their family history or because they are African-American. Participants also have the opportunity to be involved in innovative prostate cancer research.

Dr. Giri joined Fox Chase in 2004 with a dual appointment in the population and medical science divisions. In this role, she conducted research on the molecular genetics of prostate cancer, risk assessment and cancer susceptibility and also served as a clinic physician for the Prostate Cancer Risk Assessment Program. She also, as an attending physician in the medical oncology department, has treated patients with prostate, bladder, kidney, and breast cancers.  Her current research interest is focused on the clinical characterization of genetic markers of risk for prostate cancer in high-risk men and developing genetic testing models for these men.

Previously, Dr. Giri was at the University of  Michigan Medical Center, where she completed her residency in internal medicine and a fellowship in hematology and oncology. She received the Mark Roth, MD, Memorial Research Award for excellence in research during her fellowship.  She was also attending physician for ambulatory-care medicine at the Ann Arbor Veterans Administration Hospital in Ann Arbor, Michigan.

Dr. Giri has received a number of grants reflecting her commitment to research in the field of prostate cancer. The American Cancer Society awarded her the Special Interest Award to investigate the role of DNA mismatch repair defects in prostate cancer susceptibility. She also received a five-year career development grant from the Department of Defense to study genetic variants in prostate cancer risk. In an earlier project, she explored the association between Agent Orange and prostate cancer through funding from the Specialized Program of Research Excellence at the University of Michigan.  The Pennsylvania Department of Health has also awarded funds to Dr. Giri to advance prostate cancer early detection measures in PRAP. 

Dr. Giri is an active member of many professional organizations. She is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. She is also on the National Cancer Institute's PDQ Cancer Genetics Editorial Board and the National Comprehensive Cancer Network’s Prostate Cancer Early Detection Panel.

She received her BS from Pennsylvania State University and her MD from Jefferson Medical College in Philadelphia.